Drug Profile
Remibrutinib - Novartis
Alternative Names: LOU-064; LOU064-NXA; NVP-LOU064-NXALatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Class Amines; Anti-inflammatories; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Ethers; Fluorobenzenes; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic urticaria; Multiple sclerosis
- Phase II Hidradenitis suppurativa; Peanut hypersensitivity
- Discontinued Asthma; Atopic dermatitis; Sjogren's syndrome
Most Recent Events
- 19 Jan 2024 Novartis Pharmaceuticals completes a phase III REMIX-1 trial in Chronic-urticaria (In the elderly, Treatment-experienced, In adults) in Turkey, Russia, Taiwan, Mexico, Singapore, South Korea, Italy, Japan, Puerto Rico, India, France, Czech Republic, Colombia, Bulgaria, Australia, Argentina, Argentina, USA (PO) (NCT05030311) (EudraCT2021-000471-37)
- 31 Dec 2023 Discontinued - Phase-II for Sjogren's syndrome in Germany, Denmark, Spain, USA, Australia, Belgium, Hungary, United Kingdom, Taiwan, Switzerland, China, Bulgaria (PO)
- 14 Dec 2023 Novartis completes phase I pharmacokinetics and safety trial in patients with varying degrees of hepatic impairment and healthy volunteers in Hungary (PO) (NCT05753592)